Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash & Equivalents (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Cash & Equivalents for 12 consecutive years, with $189.2 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 743.39% year-over-year to $189.2 million; the TTM value through Mar 2026 reached $189.2 million, up 743.39%, while the annual FY2025 figure was $213.2 million, N/A changed from the prior year.
  • Cash & Equivalents hit $189.2 million in Q1 2026 for Crescent Biopharma, down from $213.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $213.2 million in Q4 2025 and bottomed at $14.4 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $71.8 million, with a median of $51.6 million recorded in 2022.
  • Year-over-year, Cash & Equivalents plummeted 70.85% in 2024 and then skyrocketed 825.45% in 2025.
  • Crescent Biopharma's Cash & Equivalents stood at $47.9 million in 2022, then dropped by 12.7% to $41.8 million in 2023, then tumbled by 65.54% to $14.4 million in 2024, then surged by 1380.5% to $213.2 million in 2025, then fell by 11.27% to $189.2 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $189.2 million, $213.2 million, and $133.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.